ABOUT CENCORA
Cencora combines core pharmaceutical distribution with innovative business solutions to help our partners across the healthcare spectrum get medications to the patients who need them. Biopharmaceutical companies benefit from the global scale and resources of a company ranked #10 on the Fortune 500, combined with local expertise provided by more than 51,000 team members worldwide. Learn more at www.cencora.com.
We help build foundations for successful product submissions, launches, and commercialization across the globe. Our strategic, integrated solutions – encompassing regulatory, safety, market access and more – help accelerate time-to-market while optimizing patient access and revenue from marketed products.
VIDEOS AND WEBINARS
-
![GettyImages-1204037710 meeting]( "Understanding PRCI And Its Requirements")
Understanding PRCI And Its RequirementsNavigating Health Canada's clinical information disclosure process takes real precision and preparation. Ensure your submission stays compliant, on schedule, and ready for review.
-
![Cencora - ISPOR]( "Harmonizing Health Technology Assessment: PICO Consolidation Under The EU HTA Regulation")
Harmonizing Health Technology Assessment: PICO Consolidation Under The EU HTA RegulationDiscover how the EU HTA Regulation is redefining market access through PICO consolidation and learn strategic approaches to evidence generation, comparator selection, and the integration of real-world data.
-
![Cencora - Nexus 25]( "Insights For Innovation: AMCP Nexus 2025 Educational Videos")
Insights For Innovation: AMCP Nexus 2025 Educational VideosExplore our curated collection of expert-led educational sessions from AMCP Nexus 2025, covering key topics including updates on AMCP Format 5.0, strategic payer engagement tactics, AI-driven innovations, and more.
-
![Cencora - oncology webinar]( "Navigating The Regulatory Complexities Of Targeted Medicines In Oncology")
Navigating The Regulatory Complexities Of Targeted Medicines In OncologyExplore the strategic considerations for successfully navigating the regulatory complexities of targeted medicines. Learn about the challenges in translational medicine and key clinical development considerations.
-
![Cencora - Summer Shorts - stats]( "Transforming Drug Development With Statistical Science")
Transforming Drug Development With Statistical ScienceExplore how statistical science and computational biology can accelerate drug development. Learn how innovative trial designs and Bayesian statistics can lead to more efficient and successful clinical trials.
-
![Cencora - Summer Shorts - Thinking Ahead]( "Thinking Ahead: How Integrated Development Plans Improve Product Success")
Thinking Ahead: How Integrated Development Plans Improve Product SuccessHow can integrated development planning reduce development timelines and increase your chances of commercialization success? Industry experts reveal how this approach helps avoid common pitfalls.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
ARTICLES
-
![GettyImages-1181392775 lab, research]( "Navigating The Cell And Gene Regulatory Landscape")
Navigating the complex regulatory landscape is essential for cell and gene therapy success. Explore key considerations, challenges, and best practices for companies operating in this space.
-
![GettyImages-1310986619 patient]( "A Thoughtful Copay Program Design That Increased Patient Engagement")
Learn how a partnership with a pharmaceutical company to redesign patient support materials resulted in increased patient engagement and copay program utilization.
-
![iStock-1287080337-lab-microscope-scientist-research.jpg]( "Unraveling The Complexity Of Cell Therapy: Advancements And Challenges")
Cell therapy has emerged as a powerful tool for addressing critical medical challenges, but its rapid evolution necessitates a clear regulatory framework and consistent terminology.
-
![GettyImages-1055095236 patient_nurse]( "Inside The Payer Perspective On Cell And Gene Therapy Coverage")
Find out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
-
![GettyImages-1318426446 profile]( "Strategic Management Of The Mature Product Portfolio")
Explore a new outsourcing paradigm that integrates expertise, regulatory knowledge, efficiency, and cost containment, moving beyond traditional low-cost offshore staffing models.
WHITE PAPERS
-
![GettyImages-1137143869 world map]( "Unlock The Potential Of Pharmacovigilance Outsourcing")
Outsourcing pharmacovigilance can reduce overhead, strengthen compliance, and free teams to focus on innovation. Examine what a well-structured global PV model actually looks like in practice.
-
![GettyImages-692413188 lab research]( "Project Orbis Drug Registration 2025")
Project Orbis helps streamline the review and approval of oncology medicinal products through international regulatory collaboration. Learn how this framework can accelerate your regulatory strategy.
-
![GettyImages-158649166 assay]( "Unlock Oncology Success With A Comprehensive Commercialization Guide")
Navigate the complex process of bringing an oncology therapy to market, from regulatory planning to patient access and supply chain logistics, with this comprehensive handbook for developers.
PODCASTS
-
![Digital-marketing-GettyImages-1051659276]( "Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty Pharmacy")
Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty PharmacyTune in as experts discuss how biopharma companies can effectively engage healthcare decision-makers in the evolving digital landscape.
-
![Cencora PharmaLex - PlX talks 30]( "An Overview Of Contamination Control Strategy (CCS)")
An Overview Of Contamination Control Strategy (CCS)Join experts Londa Ritchey and Patrick Nieuwenhuizen as they explore the key role of a contamination control strategy in Annex 1 for ensuring patient safety and continuous manufacturing improvement.
-
![Cencora - PharmaLex Talks 28]( "Early Access Programs: What They Are And How To Plan For Them")
Early Access Programs: What They Are And How To Plan For ThemExplore how early access programs are tailored to individual sufferers of rare, ultra-rare, or life-threatening conditions, as well as cohort programs, which target groups of patients afflicted with the same disease.
-
![Cencora - PharmaLex Talks 27]( "Assessing Gaps And Achieving Compliance With Annex 1")
Assessing Gaps And Achieving Compliance With Annex 1In this podcast episode on Annex 1 compliance and gap assessment, Patrick Nieuwenhuizen shares his insights and expertise gleaned from extensive experience in pharmaceutical regulation and compliance.
-
![Cencora - PharmaLex Talks 26]( "Navigating The Process Of Technology Transfer")
Navigating The Process Of Technology TransferOlena Chervonenko, Associate Director Quality Management and Compliance at PharmaLex, provides deeper insights into technology transfer and essential factors for achieving success.
E-BOOKS AND OTHER INSIGHTS
-
![GettyImages-1055095236 patient_nurse]( "Inside The Payer Perspective On Cell And Gene Therapy Coverage")
Inside The Payer Perspective On Cell And Gene Therapy CoverageFind out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
-
![GettyImages-2235582013-prefilled-syringe-liquid-manufacturing]( "The Need For Adaptive Distribution Partners For Cell And Gene Therapies")
The Need For Adaptive Distribution Partners For Cell And Gene TherapiesOptimize your commercial strategy by exploring how adaptive distribution models navigate reimbursement challenges and improve patient access. Partner early to align workflows and ensure operational success.
-
![GettyImages-521848481 clinical trial, patient, diversity]( "Partnering With Health Systems: Essential Tips For CGT Commercialization")
Partnering With Health Systems: Essential Tips For CGT CommercializationSuccessful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
